Keryx Biopharm Inc (KERX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2018 | 06-2018 | 03-2018 | 12-2017 | 09-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -60,409 | -43,414 | -21,896 | -163,440 | -133,011 |
| Depreciation Amortization | 4,073 | 1,669 | 190 | 63,658 | 63,470 |
| Income taxes - deferred | -635 | -635 | -635 | -235 | 60 |
| Accounts receivable | -6,460 | -7,284 | -4,743 | -2,910 | -3,962 |
| Other Working Capital | -40,805 | -26,354 | -18,866 | -14,996 | -15,985 |
| Other Operating Activity | 26,058 | 21,225 | 12,520 | 24,434 | 16,115 |
| Operating Cash Flow | $-78,178 | $-54,793 | $-33,430 | $-93,489 | $-73,313 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -52 | -52 | -78 | -1,257 | -1,176 |
| Investing Cash Flow | $-52 | $-52 | $-78 | $-1,257 | $-1,176 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 25,000 | 10,000 | N/A | N/A | N/A |
| Common Stock Issued | 850 | 777 | 69 | 76,866 | 76,780 |
| Common Stock Repurchased | N/A | N/A | N/A | -302 | N/A |
| Other Financing Activity | 0 | 0 | 0 | -102 | -102 |
| Financing Cash Flow | $25,850 | $10,777 | $69 | $76,462 | $76,678 |
| Beginning Cash Position | 93,526 | 93,526 | 93,526 | 111,810 | 111,810 |
| End Cash Position | 41,146 | 49,458 | 60,087 | 93,526 | 113,999 |
| Net Cash Flow | $-52,380 | $-44,068 | $-33,439 | $-18,284 | $2,189 |
| Free Cash Flow | |||||
| Operating Cash Flow | -78,178 | -54,793 | -33,430 | -93,489 | -73,313 |
| Capital Expenditure | -52 | -52 | -78 | -1,257 | -1,176 |
| Free Cash Flow | -78,230 | -54,845 | -33,508 | -94,746 | -74,489 |